The Prognostic Value of the Metabolic Tumor Volume in FIGO stage IA to IIB Cervical Cancer for Tumor Recurrence: Measured by F-18 FDG PET/CT

PurposeThe purpose of this study was to evaluate the prognostic value of the metabolic tumor volume (MTV), in FIGO stage IA–IIB cervical cancer patients, measured by F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging.MethodsForty-five patients with invasive cervical cancer who underwent FDG-PET imaging were recruited. Metabolically active tumor regions were delineated on the pretreatment FDG-PET scans by encompassing regions equal to or greater than an standardized uptake value (SUV) of 40% of the peak tumor intensity. The relationship of the metabolic tumor volume (MTV) to the disease-free survival was analyzed. The MTV of the cervical cancer was compared with pathological and clinical prognostic factors, including lymph node metastasis, parametrial invasion, the depth of invasion, resection margins, tumor differentiation and FIGO stages.ResultsCox proportional hazard regression analysis showed that the MTV was a significant independent predictor of recurrence of cervical cancer (p = 0.027). Patients with an MTV of >20 cm3 had a significantly reduced disease-free survival compared with patients with an MTV ≤ 20 cm3 (p = 0.029). The correlation of the MTV with traditional prognostic factors showed significantly higher values in patients that were lymph node (LN) metastasis positive (p = 0.028) and parametrial invasion positive (p = 0.022). The MTV significantly differed among the groups according to tumor differentiation (p = 0.0319) and FIGO stage (p = 0.001).ConclusionThe MTV measured by FDG-PET was an independent prognostic factor for tumor recurrence in patients with stage IA–IIB cervical cancer. These findings must be confirmed by large population based prospective studies.

[1]  John P A Ioannidis,et al.  F-Fluorodeoxyglucose Positron Emission Tomography to Evaluate Cervical Node Metastases in Patients With Head and Neck Squamous Cell Carcinoma: A Meta-analysis , 2008 .

[2]  R. Coleman,et al.  Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[3]  Jeong-Won Lee,et al.  The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. , 2009, Gynecologic oncology.

[4]  H. Dittmann,et al.  Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Quynh-Thu Le,et al.  Metabolic tumor burden predicts for disease progression and death in lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[6]  A. Alavi,et al.  Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. , 2002, Journal of the American Academy of Dermatology.

[7]  George Fountzilas,et al.  Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. , 2004, International journal of radiation oncology, biology, physics.

[8]  T. Yen,et al.  Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. , 2009, Oral oncology.

[9]  K. Hatch,et al.  Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients. , 1991, Gynecologic oncology.

[10]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[11]  L. Adler,et al.  Positron E mission T omography f or E valuating P ara-aortic Nodal M etastasis i n L ocally A dvanced C ervical C ancer Before S urgical S taging: A S urgicopathologi c S tudy , 1999 .

[12]  P. Grigsby,et al.  Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[13]  R. Coleman,et al.  Positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer , 2004 .

[14]  Byung-Joo Lee,et al.  Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy , 2010, Acta oncologica.

[15]  L. Kong,et al.  Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma , 2010, Journal of Cancer Research and Clinical Oncology.

[16]  Scott T. Grafton,et al.  PET and [18F]-FDG in oncology: a clinical update. , 1996, Nuclear medicine and biology.

[17]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  P. Rubin,et al.  A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). , 2002, International journal of radiation oncology, biology, physics.

[19]  J. Ioannidis,et al.  F-Fluorodeoxyglucose Positron Emission Tomography to Evaluate Cervical Node Metastases in Patients With Head and Neck Squamous Cell Carcinoma : A Meta-analysis , 2008 .

[20]  H. Dittmann,et al.  Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? , 2006, European journal of nuclear medicine and molecular imaging.

[21]  P. Grigsby,et al.  The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival , 2007, Cancer.

[22]  Farrokh Dehdashti,et al.  Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Jeffrey D Bradley,et al.  Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. , 2002, International journal of radiation oncology, biology, physics.

[24]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[25]  S. Larson,et al.  A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. , 2007, Gynecologic oncology.

[26]  A. Jena,et al.  Magnetic resonance imaging in carcinoma cervix--does it have a prognostic relevance. , 2005, Journal of cancer research and therapeutics.

[27]  R. Hustinx,et al.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose , 1996, European Journal of Nuclear Medicine.